Genius Group Announces 2023 Financial Results, 150% Pro Forma Revenue Growth to $70.4 million
15 mai 2024 13h27 HE
|
Genius Group Limited
Singapore, May 15, 2024 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) ("Genius Group" or the "Company"), a leading provider of AI-powered, digital-first education solutions,...
Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results
29 avr. 2024 16h30 HE
|
Streamline Health Solutions, Inc.
14% growth of SaaS revenue in fiscal 2023 compared to fiscal 2022$0.4 million of adjusted EBITDA generated in the fourth quarter of fiscal 2023 compared to ($0.2 million) during the fourth quarter of...
Bullet Blockchain Announces 2023 Financial Results
29 avr. 2024 07h25 HE
|
Bullet Blockchain, Inc.
Bullet Blockchain is actively seeking to hire CFO and marketing professionals in preparation of a ramp up in growth throughout 2024 into 2025 RENO, NV, April 29, 2024 (GLOBE NEWSWIRE) -- via...
Blue Line Protection Group Provides Financial Review
24 avr. 2024 16h50 HE
|
Blue Line Protection Group, Inc.
Denver, CO, April 24, 2024 (GLOBE NEWSWIRE) -- Blue Line Protection Group Inc. (OTCQB: BLPG) is pleased to summarize the 2023 financial results. 2023 was a profitable year for the Company, as shown...
Regional Health Properties Reports Fourth Quarter and Full Year 2023 Financial Results
08 avr. 2024 09h15 HE
|
Regional Health Properties, Inc.
Collected 93% of Contractual Rent[1] Strong Operator Rent Coverage ATLANTA, GA, April 08, 2024 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “Regional Health,” “we”, “us” or...
EzFill Announces Fourth Quarter and Full Year 2023 Financial Results
02 avr. 2024 13h33 HE
|
EzFill Holdings Inc.
— 2023 Revenue Increased 54% year over year to $23.2 Million From $15.0 Million – — Reports first year with a gross profit of $1.3 million — — Gallons delivered increased 63% year over year to...
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
01 avr. 2024 07h35 HE
|
GRI Bio, Inc.
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 ...
FSI ANNOUNCES FULL YEAR, 2023 FINANCIAL RESULTS
29 mars 2024 09h21 HE
|
Flexible Solutions International, Inc
A Conference call is scheduled for Wednesday April 3rd, 2024, 11:00am Eastern Time See dial in number below VICTORIA, BRITISH COLUMBIA, March 29, 2024 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS...
Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025
27 mars 2024 12h45 HE
|
Transgene S.A.
Résultats annuels 2023 et point sur l’activité TG4050 : de nouveaux résultats attendus en 2024 sur l’actif phare de TransgeneLes autres programmes cliniques et de recherche et innovation...
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
27 mars 2024 12h45 HE
|
Transgene S.A.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity...